Emerging Diagnostic Modalities & Innovation
|5 min read
Breast Cancer Remains the Most Common Cancer in Women, with Cases Projected to Exceed 3.5 Million by 2050
Six modifiable risks drive over a quarter of healthy years lost to breast cancer
|4 min read
Digital Pathology Market Continues to Battle Low Adoption, High Costs
Analyst Imogen Fitt highlights vendors that are pushing boundaries with new digital pathology business models
|3 min read
Direct-to-Consumer Gut Microbiome Testing Kit Results Vary Between Kits and Manufacturers
The accuracy of gut health tests remains uncertain and no study has systematically evaluated their performance until now
|2 min read
Researchers Identify ‘Fingerprint’ of Gene That Commonly Causes Congenital Heart Defects
Discovery paves the way for diagnosis and targeted therapies
|3 min read
Researchers Develop New Laser Technique to Test mRNA-Based Therapeutics
Deep-UV Raman technology enables precise mRNA measurement with minimal lipid interference
|2 min read
Noninvasive ‘Fragmentome’ Test Expands Liquid Biopsy to Liver Cirrhosis and Other Conditions
The assay builds on the clinical potential of liquid biopsy platforms and could expand this technology’s utility to detect conditions besides cancer
|3 min read
AI Adoption and Evolving Leadership in Clinical Laboratories
Explore the transformative impact of artificial intelligence on executive hiring and its role in the future of lab operations
|3 min read
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
Positive results from the RETAIN-2 trial demonstrate that a response-adapted bladder-preservation approach involving neoadjuvant chemoimmunotherapy can be considered in select patients
|1 min read
Standardizing Oncology Assays: A Guide to Cell Line-Derived Reference Materials
Identify the limitations of patient tissue controls in genetic testing and examine the verification data supporting cell line-derived standardsSponsored by
|1 min read
Move Past the Limitations of Synthetic Reference Standards in Cancer Research
A review of cell line-derived reference standards for the investigation and molecular profiling of myeloid malignanciesSponsored by
|3 min read
FDA Fast-Tracks Ultra-Rare Therapies with Plausible Mechanism Guidance
Framework enables approval of individualized genome editing and RNA-based treatments when traditional trials aren’t feasible
|1 min read
